Bone Marrow Biopsies Provide Little Value for Response Assessments in Follicular Lymphoma
Researchers sought to determine the value of bone marrow biopsies in assessing responses for patients with FL.
Diagnosis & Disease Information
Odronextamab Appears Safe, Effective in Relapsed/Refractory Follicular Lymphoma
Odronextamab has demonstrated safety and efficacy in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
Tisa-Cel Improves Outcomes Vs Usual Care in Relapsed or Refractory Follicular Lymphoma
Researchers sought to determine whether tisagenlecleucel would improve clinical outcomes compared with usual care among patients with relapsed or refractory FL.
Addition of Atezolizumab to Obinutuzumab-Bendamustine Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Researchers sought to determine whether adding atezolizumab to an obinutuzumab-bendamustine chemoimmunotherapy regimen would improve survival in FL.
Usefulness of Bone Marrow Biopsy in Follicular Lymphoma Clinical Trials Questioned
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab produced an objective response rate of 80%.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...